brigatinib (Alunbrig)
Jump to navigation
Jump to search
Indications
- metastatic ALK-positive non-small cell lung cancer (NSCLC) with progression during or after treatment with crizotinib or are intolerant to crizotinib[1][2]
- may be useful as initial therapy for ALK-positive NSCLC
Dosage
- start 90 mg PO QD
- increase to 180 mg PO QD after 1 week if tolerated
- continue until disease progression or unacceptable toxicity
Tabs: 90 mg, 180 mg
Adverse effects
- most common
- most common serious adverse events
- pneumonia, interstitial lung disease
- incidence of fatal adverse events is 3.7%
Mechanism of action
- inhibits anaplastic lymphoma kinase & EGF receptor[3]
More general terms
References
- ↑ 1.0 1.1 Bankhead C FDA Approves ALK-Targeted Drug for NSCLC - Brigatinib for disease that progressed on crizotinib. MedPage Today. April 28, 2017 https://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/64923
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ 2.0 2.1 Food & Drug Administration. April 28, 2017 Brigatinib https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm
- ↑ 3.0 3.1 PubChem: 68165256
- ↑ Kim DW, Tiseo M, Ahn MJ et al Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017 Aug 1;35(22):2490-2498. Epub 2017 May 5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28475456
- ↑ Camidge DR, Kim HR, Ahn MJ et al Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379:2027-2039. Nov 22, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30280657 https://www.nejm.org/doi/full/10.1056/NEJMoa1810171